Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis

Rosana Hernando, María Estrella Drobnic, María Jesús Cruz, Adelaida Ferrer, Pilar Suñé, J. Bruno Montoro, Ramon Orriols

    Research output: Contribution to journalArticleResearchpeer-review

    23 Citations (Scopus)

    Abstract

    Objective: The therapeutic benefit of inhaled corticoids in bronchiectasis not due to cystic fibrosis is still not well documented. The aim of the present study was to assess the efficacy and safety of inhaled corticoids in this disease. Setting: This study was conducted at a tertiary university hospital in the city of Barcelona, Catalonia, (Spain). Method: A prospective, double-blind, parallel, placebomasked study was conducted. Seventy-seven patients (40 women; mean age: 68 years) were randomly assigned to receive either 400 mcg budesonide twice daily or placebo and were regularly reviewed for six months. Results: Differences in forced vital capacity and forced expiratory volume in the first second between the beginning and end of the study were not significantly lower in the budesonide group than in the placebo group, either in absolute values [-17.4 (386.9) versus -21.4 (375.5)] or in percentages [-1.9(9.5) versus -2.8 (11.6)]. Microbiological criteria applied to evaluate changes between the beginning and end of the study showed no worsening in the budesonide group compared with the control group, whereas a non-significant improvement was obtained in 8.1 %of cases in the budesonide group compared to 3 % in the placebo group. Although significance was only achieved for sputum eosinophils (p = 0.021), a consistent tendency towards improvement was also observed in secondary end-points (symptoms, number and duration of exacerbations, quality of life, sputum cytology and interleukin-8) in the budesonide group. Conclusion: Although further studies are required, inhaled corticoid treatment may be efficacious and safe in bronchiectasis not due to cystic fibrosis. © Springer Science+Business Media B.V. 2012.
    Original languageEnglish
    Pages (from-to)644-650
    JournalInternational Journal of Clinical Pharmacy
    Volume34
    Issue number4
    DOIs
    Publication statusPublished - 1 Aug 2012

    Keywords

    • Bronchiectasis
    • Budesonide
    • Inhaled corticoid

    Fingerprint

    Dive into the research topics of 'Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis'. Together they form a unique fingerprint.

    Cite this